MP18 High Dose Antipsychotic Therapy (HDAT) guideline


Category
Medicine management
Code
MP18
Issue No
4

Target Audience

All CWP staff

Purpose

To identify those patients receiving high dose antipsychotic therapy and provide details of monitoring requirements to ensure patient safety.

Origin

Lead executive
Medical Director

Author and contact number
Clinical Pharmacist
01625 508580


Policy dates & history

Implementation Date

18 July 2017

Review Date

18 July 2022

Approval Meeting

Medicines Management Group (MMG)


Appendices

Download

MP18 High Dose Antipsychotic Therapy (HDAT) Guideline Issue 4.pdf

0.58MB
Download Now
Text size A- A+
Contrast options